Neuroleptic-Induced Tardive Cervical Dystonia: Clinical Series of 20 Patients

Background: Cervical dystonia (CD) may be classified according to the underlying cause into primary or secondary CD. Previous exposure to neuroleptics is one of the main causes of adult-onset secondary dystonia. There are few reports that characterize the clinical features of primary CD and secondary neuroleptic-induced CD. Herein our aim was to investigate a series of patients with neuroleptic induced tardive CD and to describe their clinical and demographic features. Patients and Methods: We retrospectively evaluated 20 patients with neuroleptic-induced tardive CD and compared clinical, demographic and therapeutic characteristics to another 77 patients with primary CD. All patients underwent Botulinum toxin type-A therapy. Results: We did not identify any relevant clinical and demographic characteristics in our group of patients that could be used to distinguish tardive and primary CD. Conclusion: Patients with tardive CD presented demographic characteristics and disease course similar to those with primary CD.

[1]  L. Werneck,et al.  Cervical dystonia: clinical and therapeutic features in 85 patients. , 2008, Arquivos de neuro-psiquiatria.

[2]  G. Christodoulou,et al.  Treatment of severe neuroleptic-induced tardive torticollis , 2003, Annals of general hospital psychiatry.

[3]  L. Ozelius,et al.  Classification and genetics of dystonia , 2002, The Lancet Neurology.

[4]  S. Factor,et al.  Clinical comparison of tardive and idiopathic cervical dystonia , 1998, Movement disorders : official journal of the Movement Disorder Society.

[5]  C. Marsden,et al.  The natural history of tardive dystonia. A long-term follow-up study of 107 cases. , 1998, Brain : a journal of neurology.

[6]  E. Siemers,et al.  Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A , 1998, Movement disorders : official journal of the Movement Disorder Society.

[7]  Nir Giladi,et al.  Botulinum toxin in the treatment of tardive dystonia. , 1997, Journal of clinical psychopharmacology.

[8]  D. Tarsy,et al.  An open-label study of botulinum toxin A for treatment of tardive dystonia. , 1997, Clinical neuropharmacology.

[9]  H. B. Ferraz,et al.  Symptomatic Dystonia: Clinical Profile of 46 Brazilian Patients , 1992, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[10]  C. Marsden,et al.  Natural history of adult-onset idiopathic torticollis. , 1990, Archives of neurology.

[11]  J. Nutt,et al.  Epidemiology of focal and generalized dystonia in Rochester, Minnesota , 1988, Movement disorders : official journal of the Movement Disorder Society.

[12]  A. Eisen,et al.  DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLIS , 1986, The Lancet.

[13]  R. Burke,et al.  Natural history and treatment of tardive dystonia , 1986, Movement disorders : official journal of the Movement Disorder Society.

[14]  Bourdillon Jf PHENOTHIAZINE DYSKINESIA AFTER LEUCOTOMY. , 1964, Lancet.